Clinical trial · Observational
Italian Non-Interventional Study of FLT3 Mutated AML Patients
Italian Non-Interventional Study of FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Patients
NCT03547258CI-TRIAL-00044752FLAMunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study involving a retrospective and prospective collection of clinical and molecular data regarding patients with AML with FLT3+ mutations
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| FLT3-ITD Mutation | — | UNRESOLVED | — |
| FLT3-TKD Mutation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical and Molecular data collection | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AML patients
- description
- Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
- interventionNames
- Genetic: Clinical and Molecular data collection
Primary outcomes (2)
- measure
- percentage of patients FLT3 negative at diagnosis who relapse FLT3 positive;
- timeFrame
- up to 24 months
- description
- description of how the FLT3 mutational status changes during the course and management of the disease
- measure
- percentage of patients FLT3 positive at diagnosis who relapse FLT3 negative
- timeFrame
- up to 24 months
- description
- description of how the FLT3 mutational status changes during the course and management of the disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. AML patients 2. Male or Female 3. Aged ≥ 18 years 4. FLT3 mutations (ITD or TKD) positive tests performed at diagnosis or at relapse. 5. Participant is willing and able to give informed consent for participation in the study. Exclusion criteria: 1\. To be currently involved in experimental clinical protocol, or have been treated with experimental drugs are not exclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.